Peptides in Wound Care

Overview

Wound healing is a complex, multi-phase biological process that involves inflammation, proliferation, remodeling, and tissue maturation. Peptides participate in every phase of this process as natural signaling molecules, and their therapeutic potential in wound care has been extensively investigated. From endogenous peptides like growth factor fragments and antimicrobial peptides to synthetic sequences engineered for specific healing properties, the peptide wound care landscape spans both clinical products and a substantial research pipeline.

The clinical need is substantial. Chronic wounds — including diabetic foot ulcers, venous leg ulcers, and pressure injuries — affect millions of people worldwide and impose enormous healthcare costs. Standard wound care frequently fails in these populations, creating strong demand for advanced therapies. For additional background on wound healing biology, see Wound Healing Research.

Phases of Wound Healing and Peptide Involvement

Hemostasis and Inflammation

Immediately following injury, the coagulation cascade is activated and inflammatory cells are recruited. Peptides involved in this phase include:

• Thrombin-derived peptides — Fragments of thrombin (e.g., TP508/rusalatide acetate) promote wound healing independent of thrombin's coagulation activity, stimulating endothelial cell proliferation and angiogenesis
• Antimicrobial peptides — LL-37 and defensins provide immediate antimicrobial defense while also recruiting immune cells and modulating inflammatory signaling
• Complement-derived peptides — C3a and C5a fragments recruit neutrophils and macrophages to the wound site

Proliferation

During proliferation, fibroblasts deposit new extracellular matrix, keratinocytes migrate to cover the wound surface, and new blood vessels form (angiogenesis). Key peptides include:

• GHK-Cu — Copper tripeptide-1 stimulates collagen I and III synthesis, glycosaminoglycan production, and angiogenesis. It also recruits immune cells and promotes fibroblast and endothelial cell proliferation. For cosmetic applications, see Peptides in Dermatology.
• Thymosin beta-4 (TB-500) — A 43-amino-acid peptide that promotes cell migration, angiogenesis, and reduces inflammation. TB-500 has shown accelerated wound closure in multiple preclinical models.
• BPC-157 — A 15-amino-acid peptide derived from human gastric juice that promotes angiogenesis, collagen deposition, and granulation tissue formation in preclinical wound models.

Remodeling

The remodeling phase involves maturation of collagen fibers and resolution of the wound scar. Peptides that influence matrix metalloproteinase (MMP) activity and collagen cross-linking are relevant to scar quality and tensile strength recovery.

Clinical Evidence

Approved and Marketed Products

The number of peptide-based wound care products with regulatory approval remains limited, though several are marketed:

• Becaplermin (Regranex) — While technically a recombinant growth factor (PDGF-BB) rather than a peptide, becaplermin is the most established bioactive wound care product. It is approved for diabetic foot ulcers and works by stimulating chemotaxis and proliferation of wound repair cells.
• GHK-Cu formulations — Various topical formulations containing copper peptide are commercially available, primarily in cosmetic and over-the-counter wound care contexts.
• Collagen-derived peptide dressings — Wound dressings containing collagen peptide fragments that serve as chemotactic signals for fibroblasts and promote matrix deposition.

Diabetic Foot Ulcers

Diabetic foot ulcers represent the largest clinical need for advanced wound therapies. Impaired healing in diabetic patients results from peripheral neuropathy, microvascular disease, hyperglycemia-induced cellular dysfunction, and increased susceptibility to infection.

Peptide-based approaches under investigation include:

• LL-37 analogs — Address the dual challenge of infection and impaired healing in diabetic wounds, providing both antimicrobial activity and direct stimulation of re-epithelialization
• GHK-Cu — Preclinical diabetic wound models show accelerated healing with topical GHK-Cu application
• Self-assembling peptide hydrogels — Injectable scaffolds that maintain a moist wound environment, deliver bioactive signals, and protect against infection
• Thrombin-derived peptides — TP508 was evaluated in clinical trials for diabetic foot ulcers, showing trends toward improved healing rates

Burn Injuries

Burn wound care presents unique challenges including massive tissue destruction, fluid loss, infection risk, and hypertrophic scarring. Peptide research for burn wounds includes:

• Antimicrobial peptides as alternatives to topical antibiotics, particularly for drug-resistant wound infections
• Angiogenic peptides to promote vascularization of burn eschar
• Anti-fibrotic peptides to reduce hypertrophic scar formation

Surgical Wounds

Post-surgical wound management, particularly in patients with impaired healing (diabetes, immunosuppression, obesity), benefits from peptide-based interventions:

• Incision healing — GHK-Cu and TB-500 have demonstrated improved tensile strength in preclinical incisional wound models
• Anastomotic healing — BPC-157 has shown improved healing of gastrointestinal anastomoses in animal studies

Advanced Delivery Systems

Effective wound care requires sustained delivery of therapeutic agents to the wound bed. Advanced peptide delivery platforms include:

Peptide-Loaded Hydrogels

Self-assembling peptide hydrogels serve a dual purpose: the hydrogel scaffold itself promotes healing by maintaining moisture and providing mechanical support, while encapsulated bioactive peptides are released in a sustained manner as the hydrogel degrades.

Electrospun Nanofiber Dressings

Peptides can be incorporated into electrospun polymer nanofibers that mimic the structure of natural extracellular matrix, providing both a physical scaffold and controlled peptide release.

Peptide-Functionalized Dressings

Conventional wound dressings (foams, alginates, hydrocolloids) can be functionalized with covalently bound or adsorbed peptides, combining the moisture management properties of the dressing with bioactive peptide delivery.

Controlled-Release Systems

Micro- and nanoparticle encapsulation of peptides enables sustained release over days to weeks, matching the temporal requirements of different wound healing phases. This approach addresses the inherent stability challenges of peptides in the wound environment, where proteases are highly active.

Antimicrobial Peptides in Wound Infection

Wound infection is a leading cause of healing failure, particularly in chronic wounds colonized by drug-resistant organisms and biofilms. Antimicrobial peptides offer potential advantages over conventional antibiotics in wound care:

• Broad-spectrum activity against bacteria, fungi, and biofilms
• Reduced propensity for resistance development
• Dual antimicrobial and wound-healing-promoting activities (e.g., LL-37)
• Synergy with conventional antibiotics

Several AMP-based wound care products are in preclinical and early clinical development, including topical formulations and AMP-functionalized dressings.

Challenges

Translating preclinical wound healing results to clinical practice has proven difficult. Key challenges include:

• Heterogeneity of chronic wounds — Patient comorbidities, wound etiology, and local factors vary enormously, complicating clinical trial design
• Protease-rich wound environment — Active proteases in chronic wounds rapidly degrade unprotected peptides
• Regulatory pathway — Wound care products face complex regulatory requirements, particularly for chronic wound indications
• Cost — Advanced peptide therapies must demonstrate clear superiority over standard dressings to justify higher costs

Despite these challenges, the convergence of peptide therapeutics with advanced biomaterial delivery systems continues to advance the wound care field toward more effective, biologically active treatments for difficult-to-heal wounds.